Cargando…
Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
INTRODUCTION: Inadequate antibody response to mRNA SARS-CoV-2 vaccination has been described among kidney transplant recipients. Immunosuppression level and specifically, use of antimetabolite in the maintenance immunosuppressive regimen, are associated with inadequate response. In light of the seve...
Autores principales: | Yahav, Dafna, Rozen-Zvi, Benaya, Mashraki, Tiki, Atamna, Alaa, Ben-Zvi, Haim, Bar-Haim, Erez, Rahamimov, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506046/ https://www.ncbi.nlm.nih.gov/pubmed/34635537 http://dx.doi.org/10.1136/bmjopen-2021-055611 |
Ejemplares similares
-
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study
por: Yahav, Dafna, et al.
Publicado: (2022) -
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study
por: Rozen-Zvi, Benaya, et al.
Publicado: (2021) -
SARS-CoV-2 antibody dynamics among kidney transplant recipients 3 months after BNT162b2 vaccination: a prospective cohort study
por: Yelin, Dana, et al.
Publicado: (2022) -
BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study
por: Bielopolski, Dana, et al.
Publicado: (2022) -
Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)